Recent Updates
Recently added Catalysts

BreathID Hp Lab System

Phase 3

Helicobacter Pylori Infection | Small molecule | Other |Meridian Bioscience Inc|Last Updated: Dec 20, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment54
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02905825Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System PediatricsPHASE3 COMPLETED 54May 18, 2017Nov 5, 2017Dec 20, 20226 United States, Israel
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Reported Adverse Events
24 hours

Number of participants with reported adverse events after performing urea breath test

Secondary Endpoints
Percentage of Agreement
1 week
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
Indication for Helicobacter pylori testingEXPERIMENTALWalk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
Interventions
NameTypeDescription
BreathID® Hp SystemDEVICEBreath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
BreathID® Hp Lab SystemDRUGBreath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Stool TestDIAGNOSTIC_TESTEach subject was asked to perform a stool test in parallel to the breath test.
Unlock Study Design Details
Eligibility Criteria
Age Range3 Years — 18 Years
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * Be older than 3 and younger than 18 years of age * Present with a clinical indication compatible with H. pylori based on the judgement of the treating physician (such as abdominal pain, nausea, diarrhea, reflux, peptic ulcer, dyspepsia, etc., or following treatment for H.pylor...

Countries:United StatesIsrael
Unlock Eligibility Criteria